VBI Vaccines Q1 EPS $(0.73) Up From $(3.22) YoY, Sales $1.21M Up From $485.00K YoY
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines (NASDAQ:VBIV) reported a significant improvement in its Q1 financial results, with EPS losses narrowing to $(0.73) from $(3.22) YoY and sales increasing to $1.21M from $485K YoY.
May 15, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VBI Vaccines reported improved Q1 financial results with EPS losses narrowing to $(0.73) from $(3.22) YoY and sales increasing to $1.21M from $485K YoY.
The significant improvement in both EPS and sales indicates positive financial performance, which is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100